ASH 2024 Summary: Pegylated Interferon in MPN – The Who, Why, and How
A video from Jean-Jacques Kiladjian (as part of 2024 ASH Annual Meeting Insights Hub), posted on Dec 18, 2024.
Related Articles
BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Algorithm could help prevent thousands of strokes in UK each year
Tool uses machine learning to analyse medical data for red flags relating to undiagnosed atrial fibrillation
New Onset Diabetes in Pancreatic Adenocarcinoma Does Not Correlate With Molecular Subtype
Background and Objectives Studies show that new onset diabetes mellitus (DM) (NOD) predates the diagnosis of PDAC by up to 2 years. Two tumor-intrinsic molecular…
KRAS inhibitors: resistance drivers and combinatorial strategies
In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most…
